Seralutinib is under clinical development by Gossamer Bio and currently in Phase II for Pulmonary Arterial Hypertension. According to GlobalData, Phase II drugs for Pulmonary Arterial Hypertension have a 62% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Seralutinib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Seralutinib overview

Seralutinib is under development for the treatment of pulmonary arterial hypertension (PAH). It acts by targeting CSF1R, c-KIT, PDGF subtype a and PDGFB. The drug candidate is administered as an inhalation in the form of powder. It is administered orally as a capsule. It is developed based on PDGFR kinase technology.

Gossamer Bio overview

Gossamer Bio is a biopharmaceutical company that involves discovering, developing, and commercializing medicines for the disease areas of immunology, inflammation, and oncology. The company’s product portfolio includes GB002, for pulmonary arterial hypertension; GB5121 for adult patients with relapsed/refractory CNS lymphoma, and GB7208 for multiple sclerosis. The company is funded by Arch Venture Partners LP, Omega Fund Management LLC, and Hillhouse Capital Group. Gossamer Bio is headquartered in San Diego, California, the US.

For a complete picture of Seralutinib’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.